In a report released on October 14, Mike Kratky from Leerink Partners maintained a Buy rating on Vericel, with a price target of $48.00. The company’s shares closed yesterday at $33.59.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Kratky is a 4-star analyst with an average return of 8.7% and a 42.86% success rate. Kratky covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Inspire Medical Systems, and Vericel.
Currently, the analyst consensus on Vericel is a Strong Buy with an average price target of $54.00, implying a 60.76% upside from current levels. In a report released yesterday, TR | OpenAI – 4o also upgraded the stock to a Buy with a $38.00 price target.
The company has a one-year high of $63.00 and a one-year low of $29.24. Currently, Vericel has an average volume of 719.3K.
Read More on VCEL:
Disclaimer & DisclosureReport an Issue
- Vericel price target lowered to $41 from $46 at Truist
- Vericel’s Promising Growth: Buy Rating Backed by MACI Revenue Surge and Successful MACI Arthro Launch
- Vericel’s Strategic Growth and Market Expansion Drive Buy Rating
- Vericel downgraded to Neutral from Buy at BTIG
- Vericel’s Phase 3 Study on MACI: A Potential Game-Changer in Cartilage Repair
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
